A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma

Trial Profile

A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Jul 2017 Phase of the trial changed from Phase I to Phase I/II; primary endpoint of Complete response (CR) rate added hence therapuetic use added to trial focus; trial design changed from non-randomised to randomised; Planned number of patients changed from 70 to 189; treatment arm for brentuximab + ipilumumab removed.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 According to the results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology, as of 20 Jul, 2016, 10 patients (1 ineligible) have been treated with BV + Nivo.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top